TY - JOUR
T1 - Vitamin d deficiency in mycosis fungoides and sézary syndrome patients is similar to other cancer patients
AU - Talpur, Rakhshandra
AU - Cox, Katherine M.
AU - Hu, Mimi
AU - Geddes, Elizabeth R.
AU - Parker, Mary K.
AU - Yang, Betty Y.
AU - Armstrong, Patrick A.
AU - Liu, Ping
AU - Duvic, Madeleine
N1 - Publisher Copyright:
© 2014 Elsevier Inc. All rights reserved.
PY - 2014
Y1 - 2014
N2 - Vitamin D deficiency (< 30 ng/mL serum vitamin D [25(OH)D3]) found in 239 of 311 (76.9%) cutaneous T-cell lymphoma (CTCL) patients was comparable to 238 controls including 127 of 169 (75.2%) of cancer controls and 46 of 69 (66.7%) of healthy controls (P=.05, .07). Supplementation with D2 or D3 corrected only about a third of patients' levels and did not affect response to therapy.Background: The purpose of this study was to determine the prevalence of vitamin D deficiency in CTCL patients and whether supplementation corrects vitamin D deficiency or treatment outcome .Patients and Methods: Three hundred eleven CTCL patients including 27/311 (8.7%) with Sézary syndrome (SS), 169 cancer controls, and 69 normal controls from the M.D. Anderson clinics had 25(OH)D3 levels determined and categorized as deficient (< 20 ng/mL), insufficient (20-29 ng/mL), or sufficient (≥ 30 ng/mL). Clinical response was determined according to a change in percent body surface area involvement . Results: Low 25(OH)D3 (< 30 ng/mL) levels were present in 76.9% of mycosis fungoides/SS patients, 75.2% of cancer controls, and 66.7% of healthy controls (P = .05, .07) and in 30% to 39% of historical normal controls. Correction of deficiency was successful in 35% or 55 of 156 patients who were given dealer's choice of either vitamin D2 at 50,000 IU orally (p.o.) biweekly or D3 1000 IU p.o. daily. Correction of vitamin D levels was noted in 27 of 100 (27%) patients given D3 and 28 of 56 (50%) given D2. Responses to standard CTCL therapy was similar among patients with corrected and persistently low levels (P = .51). Conclusion: To our knowledge, this is the first study of vitamin D status in CTCL patients. Vitamin D deficiency was present in CTCL and other cancer patients compared with normal and historical controls. Correction of vitamin D deficiency and type of vitamin D supplementation used did not affect the overall clinical disease response .
AB - Vitamin D deficiency (< 30 ng/mL serum vitamin D [25(OH)D3]) found in 239 of 311 (76.9%) cutaneous T-cell lymphoma (CTCL) patients was comparable to 238 controls including 127 of 169 (75.2%) of cancer controls and 46 of 69 (66.7%) of healthy controls (P=.05, .07). Supplementation with D2 or D3 corrected only about a third of patients' levels and did not affect response to therapy.Background: The purpose of this study was to determine the prevalence of vitamin D deficiency in CTCL patients and whether supplementation corrects vitamin D deficiency or treatment outcome .Patients and Methods: Three hundred eleven CTCL patients including 27/311 (8.7%) with Sézary syndrome (SS), 169 cancer controls, and 69 normal controls from the M.D. Anderson clinics had 25(OH)D3 levels determined and categorized as deficient (< 20 ng/mL), insufficient (20-29 ng/mL), or sufficient (≥ 30 ng/mL). Clinical response was determined according to a change in percent body surface area involvement . Results: Low 25(OH)D3 (< 30 ng/mL) levels were present in 76.9% of mycosis fungoides/SS patients, 75.2% of cancer controls, and 66.7% of healthy controls (P = .05, .07) and in 30% to 39% of historical normal controls. Correction of deficiency was successful in 35% or 55 of 156 patients who were given dealer's choice of either vitamin D2 at 50,000 IU orally (p.o.) biweekly or D3 1000 IU p.o. daily. Correction of vitamin D levels was noted in 27 of 100 (27%) patients given D3 and 28 of 56 (50%) given D2. Responses to standard CTCL therapy was similar among patients with corrected and persistently low levels (P = .51). Conclusion: To our knowledge, this is the first study of vitamin D status in CTCL patients. Vitamin D deficiency was present in CTCL and other cancer patients compared with normal and historical controls. Correction of vitamin D deficiency and type of vitamin D supplementation used did not affect the overall clinical disease response .
KW - 25(OH)D3
KW - 25-OH vitamin D2
KW - Cutaneous T-cell lymphoma (CTCL)
KW - T-cell lymphoma
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=84922626086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922626086&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2014.06.023
DO - 10.1016/j.clml.2014.06.023
M3 - Article
C2 - 25442486
AN - SCOPUS:84922626086
SN - 2152-2650
VL - 14
SP - 518
EP - 524
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -